Pitolisant

First-in-class histamine H3 inverse agonist from Bioprojet (EU 2016) / Harmony Biosciences (US 2019, expanded 2020 cataplexy + 2024-2025 pediatric). Non-controlled, non-stimulant, no abuse liability — unique among narcolepsy drugs. A-tier evidence for narcolepsy EDS + cataplexy; B-tier for OSA-EDS adjunct; failed Phase 3 in idiopathic hypersomnia (FDA Refusal-to-File Feb 2025). Subjectively a gentle wakefulness lift with less drive/edge than modafinil and no euphoria — many users say "doesn't feel like much." For Dylan: SKIP-FOR-NOW — modafinil owns the lane at 1/100th the cost with stronger healthy-adult cognitive evidence; pitolisant is a serious clinical option only if modafinil fails or a sleep diagnosis emerges.

The H3 receptor — what it is and why blocking it matters:

Histamine H3 is a Gi/Go-coupled receptor that sits primarily on presynaptic histaminergic neurons in the tuberomammillary nucleus (TMN, the brain's main wake-promoting histamine source) and on heteroreceptors of cholinergic, dopaminergic, and noradrenergic neurons across cortex and hippocampus. Crucially, H3 is a constitutively active receptor — meaning even without ligand binding, it tonically suppresses histamine synthesis and release. This is the brain's negative feedback brake on histamine.

Pitolisant is a high-affinity inverse agonist (technically also a competitive antagonist, but the inverse agonism is the operative pharmacology) — it binds H3 and stabilizes the inactive receptor conformation, switching off the constitutive Gi signaling. The functional consequence:

1. Disinhibits histamine release from TMN. Histamine output to cortex, thalamus, and arousal nuclei rises.
2. Cortical histamine activates H1 receptors → cortical depolarization → wakefulness. This is the same pathway through which first-generation antihistamines (diphenhydramine etc.) cause sedation by blocking H1 — pitolisant works in the opposite direction by raising H1 occupancy.
3. H3 heteroreceptor blockade adds secondary release of ACh, DA, and NE in specific circuits (cortex, striatum) — modest, circuit-selective, NOT a system-wide monoamine flood.
4. Critically: does NOT activate nucleus accumbens dopamine. This is the mechanistic basis for the lack of abuse liability — pitolisant raises mesocortical DA (cognition-relevant) without raising mesolimbic DA (reward/abuse-relevant).

Pharmacokinetics:

• Oral bioavailability ~90% (very high for an oral CNS drug).
• Tmax ~3-5 hr (median 3.5 hr) — slower onset than modafinil's ~1-2 hr.
• Plasma protein binding ~91-96%.
• Half-life ~7-12 hr (effective half-life 10-12 hr; once-daily AM dosing is the FDA-recommended schedule).
• Volume of distribution ~700 L (~10 L/kg) — high tissue penetration.
• Brain penetration is high for the parent compound. Major metabolites do NOT cross the BBB and are pharmacologically inactive.
• Metabolism: primarily CYP2D6, secondarily CYP3A4 — to inactive metabolites. Renal excretion of metabolites; minimal unchanged drug.
• Steady state reached at ~5-7 days of consistent dosing.

Why titration matters: Clinical effect can take up to 8 weeks to fully manifest because (a) histaminergic system requires receptor-level adaptation, (b) titration from 8.9 → 17.8 → 35.6 mg over 3 weeks builds slowly, (c) downstream H1-mediated arousal response needs accumulation. Unlike modafinil (which works on day 1), pitolisant is a slow build-in drug.